Trials / Recruiting
RecruitingNCT06408584
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab in Patients With Region-relapsed or Progressive Esophageal Squamous Cell Carcinoma: a Single Arm, Observational Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.
Conditions
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2024-05-10
- Last updated
- 2024-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06408584. Inclusion in this directory is not an endorsement.